Predictive Health Diagnostics $10M Pre-IPO Offering
Management Q&A Webinar This Wednesday, February 10th, at 1:00 PM PT
Boustead Securities, LLC (“Boustead”) presents its latest Pre-IPO offering, Predictive Health Diagnostics (“PHD”). PHD combines science, technology, proprietary analytics and clinical studies to detect cardiovascular disease and diabetes when it can be treated or more easily prevented.
Their Protein Unstable Lesion Signature Cardiac Test (“PULS Test”) measures protein biomarkers that indicate damage to the lining of the arteries – believed to be the earliest sign of coronary artery disease. The serum blood test helps to find people that are at risk of having a heart attack in the next 5 Years. PHD’s proprietary AI technology allows them to contemporaneously evaluate multiple relevant data types to identify clinically useful relationships that may be undetected by conventional methods. In 2016, PULS Test was the winner of the AABY Award for Innovation in Healthcare.
Please join Doug Harrington, Founder and Chairman, and Matthew Nunez, CEO, for a Q&A Webinar this Wednesday, February 10th at 1:00 PM PT as they discuss how they can detect early forms of cardiovascular disease and diabetes.
Predictive Health Diagnostics Webinar
Wednesday, February 10th
1:00 PM PT
About Predictive Health Diagnostics
PHD develops, manufactures, and distributes unique diagnostic tests that can detect the early forms of cardiovascular disease and diabetes. Their PULS Test measures protein biomarkers that indicate damage to the lining of the arteries. The company was founded by medical professional Doug Harrington, who has 30+ year experience commercializing over 200 academic discoveries.
About Boustead Securities, LLC
Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com
Form CRS/Reg BI Disclaimer:
Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing,LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.
Cautionary Statement Concerning Forward-Looking Statements
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.